Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study By Sheena Cruz / 04/21/2026
Real-world Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab By Sheena Cruz / 04/21/2026
Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the OpenLabel Extension of ULTIMATE I and II Studies By admin / 04/09/2025
Safety and Tolerability of a Modified Dosing Regimen of Ublituximab: Updates from the ENHANCE Study By admin / 04/09/2025
No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS) By admin / 04/07/2025
ENABLE: the first phase 4 observational study for patients with relapsing MS treated with ublituximab in real world clinical settings By admin / 04/07/2025
Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) By admin / 04/07/2025
Early Initiation of Ublituximab Treatment is Associated with Improved Disability Outcomes Among Treatment-Naïve Participants in ULTIMATE I and II By admin / 04/17/2024
Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies By admin / 04/17/2024
MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide By admin / 04/14/2024
